These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 7528730)
1. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate). Hatano K; Goldberg JB; Pier GB Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730 [TBL] [Abstract][Full Text] [Related]
3. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. Pier GB; Grout M; Desjardins D J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427 [TBL] [Abstract][Full Text] [Related]
4. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains. Baltimore RS; Mitchell M J Infect Dis; 1980 Feb; 141(2):238-47. PubMed ID: 6444976 [TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa lipopolysaccharide: evidence that the O side chains and common antigens are on the same molecule. Hatano K; Goldberg JB; Pier GB J Bacteriol; 1993 Aug; 175(16):5117-28. PubMed ID: 7688717 [TBL] [Abstract][Full Text] [Related]
6. Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum. Speert DP; Lawton D; Mutharia LM Pediatr Res; 1984 May; 18(5):431-3. PubMed ID: 6233529 [TBL] [Abstract][Full Text] [Related]
7. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415 [TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. Pier GB; Boyer D; Preston M; Coleman FT; Llosa N; Mueschenborn-Koglin S; Theilacker C; Goldenberg H; Uchin J; Priebe GP; Grout M; Posner M; Cavacini L J Immunol; 2004 Nov; 173(9):5671-8. PubMed ID: 15494518 [TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072 [TBL] [Abstract][Full Text] [Related]
10. Polysaccharide surface antigens expressed by nonmucoid isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Pier GB; Desjardins D; Aguilar T; Barnard M; Speert DP J Clin Microbiol; 1986 Aug; 24(2):189-96. PubMed ID: 2943759 [TBL] [Abstract][Full Text] [Related]
11. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody. Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226 [TBL] [Abstract][Full Text] [Related]
12. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
13. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. Kashef N; Behzadian-Nejad Q; Najar-Peerayeh S; Mousavi-Hosseini K; Moazzeni M; Djavid GE J Med Microbiol; 2006 Oct; 55(Pt 10):1441-1446. PubMed ID: 17005795 [TBL] [Abstract][Full Text] [Related]
18. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591 [TBL] [Abstract][Full Text] [Related]
19. Polysaccharide antigens of Pseudomonas aeruginosa. Knirel YA Crit Rev Microbiol; 1990; 17(4):273-304. PubMed ID: 1698385 [TBL] [Abstract][Full Text] [Related]
20. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]